Pharmasset Inc. (fka VRUS)

[oc631]

Pharmasset Initiates Exploratory Interferon Sparing Clinical Trial of PSI-7977 for Chronic Hepatitis C

I personally like everything about this trial. Though Pharmasset is focusing on the easiest to treat patients (treatment naive Genotype 2/3) they are the first company to run a interferon free single agent trial in combination with ribavirin. It's a bold statement that no other HCV company can match.



http://investor.pharmasset.com/releasedetail.cfm?ReleaseID=536627